Study on the causes and treatment effect of asanadi gana in middle age adults with shvitra (non segmental vitiligo)

An etiopathological assessment and upashayatmaka effect of asanadi gana in middle adulthood shvitra (non segmental vitiligo population) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094355

Enrollment

Registered

2025-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Shvitra (Non segmental vitiligo) up to the maximum chronicity of 5 years based on clinical signs and symptoms. 2. Patients who are middle adulthood population (40 to 65 years of age), irrespective of gender, religion, occupation, and socioeconomic status. 3. Individuals who are willing to participate in the study. 4. Individuals willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients having conditions like Post inflammatory Hypopigmentation, Morphea, Leprosy (Pinprick test will be done for DD), Lichen sclerosis, Pityriasis alba, Leukoderma due to melanoma, Tinea versicolor, Albinism, Burn, and Wounds. 2. Patients having uncontrolled Diabetes mellitus, Hypertension, Hypothyroidism and Hyperlipidaemia. 3. Pregnant and lactating women. 4. Patient having any other severe systemic disorders. Carcinoma, Hepatic failure, CKD, SLE. 5. Patient taking oral corticosteroids. 6. Non-co-operative patients. 7.Patient who was enrolled in different study in the last 3 months.

Design outcomes

Primary

Measure	Time frame
To understand the key Nidanas (etiopathological factors) of Shvitra (Non- segmental vitiligo) among middle-adulthood population using a validated questionnaire- Integrated Etiopathological Assessment Questionnaire for Shvitra (IEAQS).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45	—

Secondary

Measure	Time frame
Clinical effectiveness of Asanadi Gana Kashaya in reducing the extent, severity, and symptomatology of vitiligo lesions, as assessed by standardized outcome measures (e.g. VETI, VIS-22).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Evaluation of the Upashayatmaka effect of Asanadi Gana Kashaya on the progression and stability of Shvitra (Non-segmental vitiligo).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Improvement in clinical features including lesion re-pigmentation, number and size of patches, and associated subjective symptoms (e.g., itching, dryness).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Biochemical assessment of treatment response through pre- and post-intervention levels of S100B and CD8+ markers as surrogate indicators of autoimmune activity and disease activity.Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45	—

Measure

Time frame

Clinical effectiveness of Asanadi Gana Kashaya in reducing the extent, severity, and symptomatology of vitiligo lesions, as assessed by standardized outcome measures (e.g. VETI, VIS-22).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Evaluation of the Upashayatmaka effect of Asanadi Gana Kashaya on the progression and stability of Shvitra (Non-segmental vitiligo).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Improvement in clinical features including lesion re-pigmentation, number and size of patches, and associated subjective symptoms (e.g., itching, dryness).Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45;Biochemical assessment of treatment response through pre- and post-intervention levels of S100B and CD8+ markers as surrogate indicators of autoimmune activity and disease activity.Timepoint: The duration of total study will be 45 days including 4 visits i.e., Day 0, Day 15, Day 30, Day 45

—

Countries

India

Contacts

Public ContactDr Geetanjali Meena

All India Institute of Ayurveda

rups.bams@gmail.com06398552356

Outcome results